SCHEMBL278381

SCHEMBL278381

CCOC(=O)c1c(N)ncn1C1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK6 P43250 1/20 0.42
ALDH1A1 P00352 7/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAOA P21397 1/20 0.41
MAPK14 Q16539 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
MAPK1 P28482 1/20 0.39
MAPT P10636 2/20 0.39
CYP19A1 P11511 2/20 0.39
POLB P06746 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21879851 0.85 ALDH1A1 (0.43) GRK6ALDH1A1HPGDMEN1GAA
SCHEMBL16268118 0.84 ALDH1A1 (0.42) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL31332814 0.83 ALDH1A1 (0.41) GRK6ALDH1A1HPGDMEN1GAA
SCHEMBL278250 0.83 ALDH1A1 (0.41) GRK6ALDH1A1HPGDMEN1GAA
SCHEMBL20370776 0.80 ALDH1A1 (0.46) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL863014 0.80 GRK6 (0.44) GRK6ALDH1A1HPGDMEN1GAA
SCHEMBL4355684 0.77 LMNA (0.46) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL28567653 0.76 LMNA (0.45) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL841972 0.75 ALDH1A1 (0.44) GRK6ALDH1A1HPGDMEN1GAA
SCHEMBL862927 0.74 PDE4A (0.42) GRK6ALDH1A1HPGDMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025026903-A1 IMIDAZO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER BAYER AKTIENGESELLSCHAFT (DE) 2025-02-06 WO disclosed
EP-2280975-B1 7H-INDOLO[2,1-A][2]BENZAZEPINE-10-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2014-01-01 EP disclosed
US-8133884-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-13 US disclosed
US-8133884-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-13 US disclosed
US-20090280083-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2009-11-12 US disclosed
US-20090280083-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090280083-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 GRK6 3852/4885ALDH1A1 163/4885HPGD 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.